An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

Alisertib (MLN8237) is an investigational, oral, selective, Aurora A kinase (AAK) inhibitor. In this phase 2 trial, 57 patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome received alisertib 50 mg BID for 7 days in 21-day cycles. Responses in 6/35 AML patients (17% respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldberg, Stuart L., Fenaux, Pierre, Craig, Michael D., Gyan, Emmanuel, Lister, John, Kassis, Jeannine, Pigneux, Arnaud, Schiller, Gary J., Jung, JungAh, Jane Leonard, E., Fingert, Howard, Westervelt, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110881/
https://www.ncbi.nlm.nih.gov/pubmed/25068104
http://dx.doi.org/10.1016/j.lrr.2014.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110881/
https://www.ncbi.nlm.nih.gov/pubmed/25068104
http://dx.doi.org/10.1016/j.lrr.2014.06.003

Ejemplares similares